Pleural disease covers a wide range of conditions affecting the thin membrane surrounding the lungs, and the medications used depend entirely on what’s causing the problem. The main drug categories include anti-inflammatory painkillers for pleurisy, antibiotics and enzyme therapy for infections, pleurodesis agents for recurring fluid buildup, tuberculosis regimens, corticosteroids for autoimmune causes, and chemotherapy drugs for cancer-related effusions. Here’s how each category works and when it’s used.
NSAIDs for Pleuritic Pain
The sharp, stabbing chest pain that worsens with breathing is often the first symptom that sends someone to a doctor. Nonsteroidal anti-inflammatory drugs are the first-line treatment for this pain. Indomethacin is the most commonly referenced NSAID for pleurisy, though ibuprofen and naproxen serve a similar role. These drugs reduce inflammation in the pleural lining while controlling pain, which makes breathing more comfortable while the underlying cause is being treated.
NSAIDs alone don’t fix pleural disease. They manage symptoms while other medications or procedures target whatever is driving the inflammation, whether that’s an infection, autoimmune condition, or something else entirely.
Antibiotics for Pleural Infections
When bacteria infect the pleural space, the condition progresses from a simple parapneumonic effusion (fluid caused by pneumonia) to a complicated infection or empyema (pus in the pleural space). Antibiotics are essential at every stage, and the choice of drug depends on what organisms are involved.
Initial treatment typically uses broad-spectrum antibiotics that cover both common bacteria types (gram-positive and gram-negative) as well as anaerobes, the oxygen-avoiding bacteria that frequently show up in pleural infections. The specific antibiotic is guided by local hospital protocols and, once available, culture results from fluid samples.
The total course of antibiotics for pleural infection is notably long compared to a standard pneumonia course. European guidelines recommend at least three weeks, and most patients receive four to six weeks of treatment. Recent trials have explored whether two to three weeks might be enough for milder cases, but the evidence isn’t strong enough yet to make shorter courses routine.
Intrapleural Enzyme Therapy for Empyema
When infected pleural fluid becomes thick, divided into pockets by fibrous strands, and difficult to drain, doctors can instill two medications directly into the pleural space to break it up. The combination is a clot-dissolving drug (tissue plasminogen activator, or tPA) paired with an enzyme that breaks down DNA from dead cells (dornase alfa, often called DNase). Together, they thin out the infected fluid and dissolve the barriers trapping it, allowing it to drain through a chest tube.
The standard regimen established in clinical trials uses 10 mg of tPA with 5 mg of DNase, delivered twice daily through the chest tube. A reduced starting dose of 5 mg of tPA with 5 mg of DNase has also shown effectiveness, with the option to escalate to the higher tPA dose if drainage is insufficient. This combination successfully manages over 90% of pleural infections without surgery.
The main risk is bleeding into the pleural space, which occurs in roughly 1 to 7% of patients across studies, with one large multicenter review placing the rate at about 4%. Systemic bleeding (elsewhere in the body) is rare. When pleural bleeding does occur, it’s usually managed by simply stopping the treatment. Around 18% of patients in one study still needed surgery after starting enzyme therapy, but this is far lower than the surgical rates seen before this combination became available.
Pleurodesis Agents for Recurring Effusions
When fluid keeps coming back, particularly in cancer-related effusions, the goal shifts to permanently sealing the pleural space so fluid can’t accumulate. This is done by introducing an irritant that causes the two layers of the pleura to stick together, a procedure called pleurodesis.
Talc is the most effective and widely used agent. Delivered as a slurry through a chest tube, talc pleurodesis achieves a success rate of about 85% at 30 days. That outperforms the alternatives: bleomycin succeeds roughly 79% of the time, tetracycline about 76%, and doxycycline around 63%. The particle size of the talc matters. Very fine particles can be absorbed into the bloodstream and cause serious complications, including acute lung injury, so medical-grade talc with appropriate particle sizing is essential.
Tuberculosis Drug Regimens
Pleural tuberculosis is one of the most common forms of TB outside the lungs, and it requires a full course of anti-tuberculosis medications. The standard regimen lasts six months and uses four drugs in combination.
The first two months (the initial phase) combine isoniazid, rifampin, pyrazinamide, and ethambutol. These can be given daily throughout, or in various intermittent schedules such as daily for two weeks followed by twice weekly. After this intensive phase, treatment continues with just isoniazid and rifampin for a minimum of four additional months. If imaging shows cavities in the lung or cultures are still positive at the two-month mark, the continuation phase extends by three more months, bringing the total to nine months.
This is the same core regimen used for pulmonary TB, and completing the full course is critical. Stopping early risks relapse and the development of drug-resistant strains.
Corticosteroids for Autoimmune Pleurisy
When pleural inflammation stems from an autoimmune condition like rheumatoid arthritis or lupus, corticosteroids are a key part of treatment. Prednisolone is the most commonly used, often at low doses of around 5 mg per day as an add-on to disease-modifying drugs that target the underlying condition.
For acute flares causing significant pleural symptoms, short-term higher doses may be used before tapering back down. The challenge with corticosteroids in autoimmune pleurisy is that many patients end up on them long-term, even though guidelines generally recommend short courses. Research in rheumatoid arthritis patients aged 65 and older found that low-dose prednisolone at 5 mg daily for up to two years was effective without dramatically increasing side effects compared to alternatives. Still, the goal is usually to control the autoimmune disease well enough with other medications that steroids can be minimized or stopped.
Chemotherapy and Targeted Drugs for Malignant Effusions
Cancer-related pleural effusions can be treated not only by draining and sealing the space, but also by delivering anti-cancer drugs directly into the pleural cavity. This approach, called intracavitary or thoracic perfusion chemotherapy, puts high concentrations of medication right where the tumor cells are.
Platinum-based drugs, particularly cisplatin and carboplatin, are the most widely used agents for this purpose. Cisplatin has stronger antitumor activity but causes more nausea and kidney stress, while carboplatin is harder on bone marrow. Bleomycin also serves double duty here, functioning both as a pleurodesis agent and a chemotherapy drug.
Bevacizumab, a drug that blocks the growth of new blood vessels feeding tumors, has shown particular promise when combined with cisplatin and delivered into the pleural space. In studies of malignant pleural effusions, the combination of bevacizumab with cisplatin achieved response rates around 83%, compared to 50% for cisplatin alone. The drug works by cutting off the blood vessel growth that tumors rely on to produce excess fluid. Other drugs targeting the same blood vessel growth pathway show similar benefits when paired with platinum-based chemotherapy, with combination treatment reaching response rates above 80% compared to roughly 65% with chemotherapy alone.
Why Some Drugs Are Given Directly Into the Pleural Space
A distinctive feature of pleural disease treatment is that many medications work best when delivered straight into the chest cavity rather than taken as pills or given intravenously. This applies to enzyme therapy for empyema, talc for pleurodesis, and chemotherapy for malignant effusions. The reason is straightforward: the pleural space is somewhat isolated from the general circulation, so systemic drugs may not reach it in high enough concentrations. Delivering medication directly through a chest tube or catheter puts the full dose exactly where it’s needed while limiting the amount that reaches the rest of the body and causes side effects.
This local delivery approach does require having a chest tube or catheter already in place, which means it’s typically used in patients who are already undergoing drainage. The medications are diluted in saline, instilled through the tube, and left to dwell in the pleural space for a set period before the tube is unclamped to allow drainage.